Accessibility Menu
Eisai logo

Eisai(OTC) ESALF

Market Cap$8.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+52%
5 Year-60%
1 Year-4%
1 Month+10%
$28.71
+4.23%
+1.16Today
Eisai last closing stock price
MetricPriceDate
Last closeUSD 28.712026-08-13
Eisai stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 28.712026-08-05
1 month+9.67%USD 26.182026-07-14
3 month-0.2%USD 28.762026-05-15
Year to date-1.79%USD 29.232025-12-31
1 year-4.33%USD 30.002025-08-12
3 year-51.84%USD 59.602023-08-14
5 year-60.18%USD 72.082021-08-10
Since inception+51.8%USD 18.912003-07-17

Eisai Financials at a Glance

Market Cap

$8.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥859.67B

Net Income (TTM)

¥42.33B

EPS (TTM)

$0.97

P/E Ratio

29.53

Dividend

$1.04

Beta (Volatility)

0.09 (Low)

Price

$28.71

Volume

75

Open

$28.71

Previous Close

$28.71

Daily Range

$28.71 - $28.71

52-Week Range

$23.88 - $35.83

Estimated Earnings Date

Nov 10, 2026

ESALF News

Scale

FDA Asks That Weight Loss Drug Belviq Be Pulled From the Market

Brian Orelli, PhDFeb 13, 2020
AD

Why Biogen Stock Is Crashing Today

George Budwell, PhDMar 21, 2019
Alz

Why Biogen's Stock Is Slumping Today

George Budwell, PhDJul 26, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eisai

Eisai Co., Ltd. is a Tokyo-based pharmaceutical company specializing in the development and marketing of a diverse range of medicinal products. The company focuses on neurological conditions and oncology, providing innovative solutions to improve patient outcomes.

Products and Services
  • Aricept for Alzheimer's disease and dementia
  • Lenvima, a targeted therapy for various cancers
  • Consumer health products like Chocola BB Plus
Growth Outlook
  • Strong pipeline with multiple new drug candidates in development
  • Increasing global demand for neurological and oncology treatments
  • Expansion into emerging markets to drive revenue growth
Financial Highlights
  • Recent quarterly revenue of 206.72 billion JPY, showing resilience
  • Trailing twelve months (TTM) net income margin of 4.67%
  • Dividend yield of 3.44%, reflecting commitment to shareholder returns
Eisai Co., Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the fields of neurology and oncology. The company's flagship products, such as Aricept and Lenvima, address significant medical needs, contributing to its robust market position. Recent financial performance indicates a solid revenue base, with a TTM net income margin that highlights operational efficiency. The commitment to innovation is evident in the ongoing development of new therapies, which positions the company well for future growth. Additionally, the attractive dividend yield underscores Eisai's dedication to returning value to shareholders, making it a noteworthy consideration for potential investors.
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,543

CEO

Haruo Naito

Website

www.eisai.co.jp

Headquarters

Tokyo, TY 112-8088, JP

ESALF Financials

Key Financial Metrics (TTM)

Gross Margin

76.70%

Operating Margin

5.11%

Net Income Margin

4.94%

Return on Equity

4.77%

Return on Capital

3.71%

Return on Assets

2.72%

Earnings Yield

3.39%

Dividend Yield

3.64%

Payout Ratio

1.07%

Stock Overview

Market Cap

$8.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

282.46M

Volume

75

Avg. Volume

373.079

Financials (TTM)

Gross Profit

¥659.30B

Operating Income

¥43.75B

EBITDA

¥93.47B

Operating Cash Flow

¥58.02B

Capital Expenditure

-¥15.12B

Free Cash Flow

¥42.90B

Cash & ST Invst.

¥309.48B

Total Debt

¥269.38B

Eisai Performance Analysis

Eisai annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 5,495,248,038-18.3%
20242024-03-31JPY 5,136,302,320-6.5%
20252025-03-31JPY 5,178,078,7190.8%
20262026-03-31JPY 5,477,248,5255.8%
Eisai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-1.7%
Q32025-12-3110.0%
Q42026-03-31-6.1%
Q12026-06-3012.5%
Eisai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.43-4.1%
20242024-03-31JPY 1.02-28.3%
20252025-03-31JPY 1.074.9%
20262026-03-31JPY 0.91-15.5%
Eisai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-29.8%
Q32025-12-3166.9%
Q42026-03-31-119.0%
Q12026-06-30656.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

¥232.64B

+14.2%

Gross Profit

¥181.92B

+13.1%

Gross Margin

78.20%

N/A

Market Cap

$8.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$769.04K

N/A

Employees

10,543

N/A

Net Income

¥18.11B

+24.5%

EBITDA

¥33.87B

+2.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

¥309.48B

+8.4%

Total Debt

¥269.38B

+12.7%

Accounts Receivable

¥251.29B

+14.2%

Inventory

¥279.97B

+23.2%

Long Term Debt

¥183.27B

+83.6%

Short Term Debt

¥86.11B

-38.1%

Return on Assets

2.72%

N/A

Return on Invested Capital

3.76%

N/A

Free Cash Flow

-¥6.80B

-96.6%

Operating Cash Flow

-¥2.57B

-333.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GIFLFGrifols, S.A.
$11.76+0.00%
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
WILLFDemant A/S
$44.88+0.00%
WILYYDemant A/S
$23.00+2.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.28+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.63-0.00%
ONDSOndas
$9.32+0.05%
INTCIntel
$103.46-0.01%

Questions About ESALF

What is the current price of Eisai?

Eisai is trading at $28.71 per share.

What is the 52-week range for Eisai?

Over the past 52 weeks, Eisai has traded between $23.88 and $35.83.

How much debt does Eisai have?

As of the most recent reporting period, Eisai reported total debt of ¥1.67B.

How much cash does Eisai have on hand?

Eisai reported ¥1.92B in cash and cash equivalents in its most recent financial results.

What is Eisai’s dividend yield?

Eisai currently has a dividend yield of 3.64%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services